Denali Therapeutics Inc. DNLI Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $208.43M+18.1% | $176.54M+37.2% | $128.68M-41.4% | $219.54M-25.6% | ||
| $662.55M+0.8% | $657.37M-27.6% | $907.41M-18.8% | $1.12B+95.5% | ||
| $900.66M+4.2% | $864.44M-18.8% | $1.06B-22.5% | $1.37B+52.9% | ||
| $52.4M-5.1% | $55.24M+21.2% | $45.59M+3.4% | $44.09M+13.4% | ||
| $0— | —— | —— | —— | ||
| $1.14B-16.7% | $1.37B+19.1% | $1.15B-21.0% | $1.46B+4.0% | ||
| $505K-95.5% | $11.14M+17.4% | $9.48M+240% | $2.79M-41.6% | ||
| $83K— | —— | —— | —— | ||
| $98.35M-3.8% | $102.21M+31.1% | $77.98M-78.6% | $363.92M-3.8% | ||
| $131.09M-9.3% | $144.5M+17.5% | $122.96M-70.6% | $417.81M+376,307% | ||
| $1.89M+6.8% | $1.77M+3.3% | $1.71M+1.5% | $1.69M+8.9% | ||
| -$2.05B-33.3% | -$1.54B-37.9% | -$1.12B-15.0% | -$970.99M-50.5% | ||
| $1.01B-17.6% | $1.23B+19.3% | $1.03B-1.1% | $1.04B+8.3% | ||
| $1.14B-16.7% | $1.37B+19.1% | $1.15B-21.0% | $1.46B+4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Denali Therapeutics Inc. cover its short-term obligations?
- Its current ratio is 9.28 — current assets exceed current liabilities.
- Where does Denali Therapeutics Inc.'s balance sheet data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.